The landscape of Alzheimer's treatment is evolving rapidly. At the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, researchers presented breakthrough data on treatments that go far beyond amyloid-clearing therapies like Leqembi and Kisunla.

In this podcast episode, I break down seven treatments that could be available—or very close to available—in 2026:

1. Remternetug - Anti-tau antibody that could be combined with existing treatments

2. ALZ-801 - Oral amyloid blocker (no infusions required)

3. Masitinib - Anti-inflammatory targeting neuroinflammation

4. Fosgonimeton - Synaptic restoration therapy

5. Gantenerumab - High-dose amyloid therapy showing renewed promise

6. Semaglutide (Ozempic) - Repurposed diabetes drug with neuroprotective effects

7. Combination therapy trials - Multiple mechanisms working together

We're also seeing a major shift toward earlier intervention—treating people before symptoms appear using biomarker testing, blood tests, and PET scans.

What this means for families:

• More treatment options beyond current FDA-approved therapies

• Oral medications in development (reducing infusion burden)

• Different mechanisms for patients who don't respond to amyloid-clearing therapies

• Earlier intervention strategies that could preserve more function

What you should do now:

• Maximize current treatment options (Leqembi, Kisunla)

• Consider clinical trial participation

• Explore biomarker testing if you're at risk

• Stay informed about the treatment pipeline

• Connect with research centers and advocacy organizations

Listen to the full episode for detailed analysis of each treatment, FDA approval timelines, patient eligibility criteria, and actionable steps you can take today.

This episode is a love letter to every person who has ever said "yes" to Alzheimer's research when outcomes were uncertain. Behind every breakthrough treatment stand volunteers whose courage makes medical advances possible.

Episode highlights:

✓ Why clinical trial volunteers give "the ultimate gift"

✓ What participation actually requires (trust, time, risk, hope)

✓ My mother's 2019 decision to enroll in Leqembi trials

✓ Milestones her courage gave our family

✓ Why her gift extends to people she'll never meet

✓ How one person's sacrifice ripples across generations

✓ Concrete ways to honor and support clinical research

The numbers that matter:

• 1,795 Clarity AD participants made Leqembi possible

• 1,736 TRAILBLAZER-ALZ 2 participants made Kisunla real

• Thousands currently enrolling in trials for future treatments

• One person's courage = changed trajectory for millions

What clinical trial participation requires:

→ Trust in uncertain outcomes

→ Frequent MRIs and brain scans → Regular multi-hour infusions

→ Cognitive testing highlighting decline → ARIA risk acceptance

→ Months or years of commitment

→ Hope for others without guaranteed personal benefit

This episode honors every volunteer—past, present, and future—who chose courage over fear.

Timeline: 0:00 - Cold open: The ultimate gift 2:00 - Why this gift matters 4:00 - My mother's decision (2019) 8:30 - What her courage gave us 14:00 - The unnamed thousands 18:30 - Science behind the sacrifice 22:00 - Gratitude in the season of giving 26:00 - How we honor this gift 28:30 - Closing: You're not alone

To every clinical trial volunteer: Thank you. Your gift is why we have hope. ❤️

#AlzheimersClinicalTrials #Leqembi #Kisunla #MedicalResearch #ClinicalTrialVolunteers #AlzheimersBreakthrough #UltimateGift #AlzheimersPodcast

Oral Alzheimer's medications could revolutionize treatment access for millions of families. In this episode, Alzheimer's educator and caregiver Teri Youngdale breaks down everything you need to know about the new oral anti-amyloid drugs in development—who might qualify, how they compare to infusions like Leqembi and Kisunla, and what to expect if these pills become available.

🎙️ What You'll Learn:

• How oral Alzheimer's medications work to clear amyloid plaques

• Key differences between pills and IV infusion treatments

• Who qualifies for oral anti-amyloid therapy

• Potential benefits: convenience, cost savings, and greater access

• Monitoring requirements and ARIA risks explained

• Real stories from families navigating treatment decisions

• Timeline for FDA approval and availability

📌 Perfect for: Alzheimer's caregivers, families exploring treatment options, those living far from infusion centers, people with MCI or early-stage Alzheimer's, healthcare advocates, and anyone seeking the latest Alzheimer's research updates.

‍ ‍

🔗 RESOURCES:

📅 Book Your Free 10-Minute Clarity Call: https://www.memorytreatmentadvisors.com/schedule

📰 Weekly Blog (Tuesdays at 9AM): https://www.alzheimersurvivor.com

🎧 Subscribe to Surviving Alzheimer's Podcast: New episodes every Thursday at 9AM

💬 NEXT WEEK: Clinical Trials Demystified - Learn how clinical trials work, who qualifies, and whether trial participation might be right for your family. Don't miss it!

ABOUT TERI YOUNGDALE: Teri is an Alzheimer's educator, speaker, author, and founder of Memory Treatment Advisors and Alzheimer's Survivor. As her mother's study partner during the Leqembi clinical trial since 2019, Teri brings firsthand experience navigating cutting-edge Alzheimer's treatments. Her mission: provide clarity, courage, and care for those facing Alzheimer's Disease

CONNECT WITH TERI: 🌐 Website: https://www.alzheimersurvivor.com 🌐 Memory Treatment Advisors: https://www.memorytreatmentadvisors.com 📧 Alzheimer's Treatment Care Circle: Every Thursday night & Saturday afternoon on Zoom

#AlzheimersAwareness #OralMedications #LeqembiTreatment #AlzheimersCaregivers #DiseaseModifyingTherapy #AlzheimersResearch #ClinicalTrials #MemoryTreatmentAdvisors #AlzheimersSurvivor #DementiaSupport #CaregiverSupport #AlzheimersEducation #AntiAmyloidTherapy #ARIA #AlzheimersPill #NewTreatmentOptions #AlzheimersHope #MCITreatment #EarlyAlzheimers #AlzheimersAdvocacy

⚠️ DISCLAIMER: This podcast is for educational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals before making treatment decisions.

👍 If this episode helped you, please

• Like this video

• Subscribe for weekly episodes

• Share with families navigating Alzheimer's

• Leave a comment with your questions or experiences

• Join our Alzheimer's Treatment Care Circle community

Your engagement helps more families find this life-changing information. Thank you for being part of this community

Caring for someone on new Alzheimer’s treatments like Leqembi or Kisunla often comes with uncertainty—and side effects can feel overwhelming for families and caregivers. In this episode, Teri shares practical strategies for recognizing, monitoring, and managing potential side effects while keeping care grounded in compassion and clarity.

💜 What you’ll learn:

• Common side effects of Alzheimer’s treatments and how to track them

• Practical tools for communicating with doctors and care teams

• How caregivers can reduce anxiety and build confidence during treatment

• Why support systems matter and how to strengthen yours

This episode is about more than symptoms—it’s about empowering caregivers with knowledge, tools, and courage to walk this journey with hope.

✨ Join the conversation, and let’s navigate this path together.

👉 Learn more at Memory Treatment Advisors: https://www.memorytreatmentadvisors.com/

#Alzheimers #Leqembi #Kisunla #CaregiverSupport #AlzheimersPodcast #SurvivingAlzheimers